<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548671" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548671/" /><meta name="ncbi_pagename" content="Atomoxetine - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Atomoxetine - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Atomoxetine" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2017/07/27" /><meta name="citation_pmid" content="31643982" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548671/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Atomoxetine" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2017/07/27" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548671/" /><meta name="description" content="Atomoxetine is a selective norepinephrine reuptake inhibitor used primarily for therapy of attention deficit hyperactivity disorder. Atomoxetine has been linked to a low rate of serum aminotransferase elevations and to rare cases of acute, clinically apparent liver injury." /><meta name="og:title" content="Atomoxetine" /><meta name="og:type" content="book" /><meta name="og:description" content="Atomoxetine is a selective norepinephrine reuptake inhibitor used primarily for therapy of attention deficit hyperactivity disorder. Atomoxetine has been linked to a low rate of serum aminotransferase elevations and to rare cases of acute, clinically apparent liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548671/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Atomoxetine/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548671/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8810BD0466D11100000000029E00B5.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548671_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548671_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Atezolizumab/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Atorvastatin/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548671_"><span class="title" itemprop="name">Atomoxetine</span></h1><p class="small">Last Update: <span itemprop="dateModified">July 27, 2017</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Atomoxetine.OVERVIEW"><h2 id="_Atomoxetine_OVERVIEW_">OVERVIEW</h2><div id="Atomoxetine.Introduction"><h3>Introduction</h3><p>Atomoxetine is a selective norepinephrine reuptake inhibitor used primarily for therapy of attention deficit hyperactivity disorder. Atomoxetine has been linked to a low rate of serum aminotransferase elevations and to rare cases of acute, clinically apparent liver injury.</p></div><div id="Atomoxetine.Background"><h3>Background</h3><p>Atomoxetine (a" toe mox' e teen) is a selective norepinephrine reuptake inhibitor that blocks the presynaptic norepinephrine transporter leading to an increase in levels of this potent neurotransmitter, predominantly in the central nervous system. Therapy with atomoxetine has been shown to lead to improvements in levels of psychological functioning and performance in children and adults with suspected attention deficit hyperactivity disorder. Atomoxetine was approved for use in adults, adolescents and children above the age of 6 years with attention deficit hyperactivity disorder in the United States in 2002. Atomoxetine is available in capsules of 10, 18, 25, 40, 60, 80 and 100 mg in generic forms and under the brand name Strattera. The recommended initial dosage in adults is 40 mg once daily, with subsequent increases to a maintenance dose which averages 60 to 100 mg daily. The dosage in children is based upon body weight. Common side effects include headache, insomnia, irritability, dry mouth, erectile dysfunction, urinary hesitancy, gastrointestinal upset, nausea, constipation and rash. Uncommon but potentiall severe adverse events include suicidal ideation and behavior, cardiovascular symptoms and events, manic or aggressive behavior and hypersensitivity reactions.</p></div><div id="Atomoxetine.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Atomoxetine has been linked to serum aminotransferase elevations in a small proportion of patients (~0.5%). More importantly, there have been several reports of clinically apparent acute liver injury due to atomoxetine. The onset of injury was within 3 to 12 weeks of starting the medication. The typical pattern of serum enzyme elevations was hepatocellular with marked increases in serum aminotransferase levels (often &#x0003e;20 times upper limit of normal) and clinical features that resembled acute viral hepatitis. Most cases have been self-limited, but instances of acute liver failure sometimes requiring emergency liver transplantation have been reported. Immunoallergic features were not found, but several patients with acute injury had antinuclear antibody and at least one patient had other features that resembled autoimmune hepatitis (with typical liver histology and high levels of immunoglobulins in serum).</p><p>Likelihood score: C (probable cause of clinically apparent liver injury).</p></div><div id="Atomoxetine.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism by which atomoxetine might cause liver injury is unknown. Atomoxetine is extensively metabolized in the liver by the cytochrome P450 system, predominantly CYP 2D6 and production of a toxic intermediate or immunogenic byproduct are reasonable explanations.</p></div><div id="Atomoxetine.Outcome_and_Management"><h3>Outcome and Management</h3><p>The liver injury due to atomoxetine varies from minor, transient and asymptomatic elevations in serum aminotransferase levels to clinically apparent hepatitis that can be prolonged and even fatal. Chronic liver injury and vanishing bile duct syndrome due to atomoxetine have not been described. Atomoxetine should be discontinued if there are any symptoms of liver injury that accompany serum enzyme elevations. There does not seem to be cross reactivity to hepatic injury with the other agents used for attention deficit hyperactivity disorder, but there may be cross reactivity with other norepinephrine reuptake inhibitors.</p><p>Drug Class: <a href="/books/n/livertox/CNSStimulants/">CNS Stimulants</a></p></div></div><div id="Atomoxetine.CASE_REPORT"><h2 id="_Atomoxetine_CASE_REPORT_">CASE REPORT</h2><div id="Atomoxetine.Case_1._Acute_hepatitis_in_a"><h3>Case 1. Acute hepatitis in a child treated with atomoxetine.</h3><p>[Modified from Case 1 of: Lim JR, Faught PR, Chalasani NP, Molleston JP. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr 2006; 148: 831-4. <a href="https://www.ncbi.nlm.nih.gov/pubmed/16769398" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 12 year old girl with attention deficit-hyperactivity disorder developed abdominal pain, nausea, diarrhea and jaundice three weeks after restarting atomoxetine (40 mg daily). She had no previous history of liver disease or risk factors for viral hepatitis. She had received atomoxetine for approximately one year, but stopped taking it when she ran out of the medication, leading to an interruption of therapy for 6 weeks before restarting. She was not taking any other medications, over-the-counter drugs or herbals. On examination, she was jaundiced and had mild right upper quadrant tenderness without hepatomegaly or other manifestations of chronic liver disease. She had no fever or rash. Laboratory tests showed a total bilirubin of 9.1 mg/dL (direct 5.5 mg/dL) and marked elevations in serum aminotransferase levels (<a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> 3264 U/L, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> 2999 U/L), with minimal increase in alkaline phosphatase (231 U/L) and gamma glutamyl transpeptidase (108 U/L) (Table). Tests for hepatitis A, B and C were negative. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.antinuclear-antibody/">Antinuclear antibody</a> was positive in a titer of 1:160; smooth muscle antibody was negative. There was no hypergammaglobulinemia, and total IgG levels were normal (769 mg/dL). A liver biopsy showed focal hepatocyte necrosis and marked portal and parenchymal inflammatory infiltrates, with minimal fibrosis and normal bile ducts. Atomoxetine was discontinued and she was monitored on no specific therapy. She improved markedly over the next six weeks, and liver tests were normal when tested six months later.</p><div id="Atomoxetine.Key_Points"><h4>Key Points</h4><div id="Atomoxetine.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548671/table/Atomoxetine.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Atomoxetine.T1_lrgtbl__"><table><thead><tr><th id="hd_h_Atomoxetine.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Medication:</th><td rowspan="1" colspan="1" style="vertical-align:top;">Atomoxetine (40 mg daily)</td></tr></thead><tbody><tr><th headers="hd_h_Atomoxetine.T1_1_1_1_1" id="hd_b_Atomoxetine.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</th><td headers="hd_b_Atomoxetine.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular (R=39)</td></tr><tr><th headers="hd_h_Atomoxetine.T1_1_1_1_1" id="hd_b_Atomoxetine.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Severity:</th><td headers="hd_b_Atomoxetine.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">3+ (jaundice, hospitalization)</td></tr><tr><th headers="hd_h_Atomoxetine.T1_1_1_1_1" id="hd_b_Atomoxetine.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Atomoxetine.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">3 weeks (re-exposure)</td></tr><tr><th headers="hd_h_Atomoxetine.T1_1_1_1_1" id="hd_b_Atomoxetine.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</th><td headers="hd_b_Atomoxetine.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">~6 weeks</td></tr><tr><th headers="hd_h_Atomoxetine.T1_1_1_1_1" id="hd_b_Atomoxetine.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</th><td headers="hd_b_Atomoxetine.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">None</td></tr></tbody></table></div></div></div><div id="Atomoxetine.Laboratory_Values"><h4>Laboratory Values</h4><div id="Atomoxetine.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548671/table/Atomoxetine.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Atomoxetine.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Atomoxetine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Atomoxetine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Atomoxetine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> (U/L)</th><th id="hd_h_Atomoxetine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Atomoxetine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> (mg/dL)</th><th id="hd_h_Atomoxetine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Atomoxetine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Atomoxetine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Atomoxetine.T2_1_1_1_3 hd_h_Atomoxetine.T2_1_1_1_4 hd_h_Atomoxetine.T2_1_1_1_5 hd_h_Atomoxetine.T2_1_1_1_6" colspan="4" rowspan="1" style="vertical-align:top;">Atomoxetine (40 mg daily) started</td></tr><tr><td headers="hd_h_Atomoxetine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">3 weeks</td><td headers="hd_h_Atomoxetine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Atomoxetine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">1979</td><td headers="hd_h_Atomoxetine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">363</td><td headers="hd_h_Atomoxetine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">8.0</td><td headers="hd_h_Atomoxetine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Atomoxetine stopped</td></tr><tr><td headers="hd_h_Atomoxetine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">5 weeks</td><td headers="hd_h_Atomoxetine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td><td headers="hd_h_Atomoxetine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Atomoxetine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Atomoxetine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">9.8</td><td headers="hd_h_Atomoxetine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Liver biopsy</td></tr><tr><td headers="hd_h_Atomoxetine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">7 weeks</td><td headers="hd_h_Atomoxetine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Atomoxetine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">1438</td><td headers="hd_h_Atomoxetine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">177</td><td headers="hd_h_Atomoxetine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">2.6</td><td headers="hd_h_Atomoxetine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Atomoxetine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">9 weeks</td><td headers="hd_h_Atomoxetine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">6 weeks</td><td headers="hd_h_Atomoxetine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">107</td><td headers="hd_h_Atomoxetine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">182</td><td headers="hd_h_Atomoxetine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.6</td><td headers="hd_h_Atomoxetine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Atomoxetine.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">7 months</td><td headers="hd_h_Atomoxetine.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">6 months</td><td headers="hd_h_Atomoxetine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">&#x0003c;15</td><td headers="hd_h_Atomoxetine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">176</td><td headers="hd_h_Atomoxetine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.3</td><td headers="hd_h_Atomoxetine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Atomoxetine.T2_1_1_1_1 hd_h_Atomoxetine.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Atomoxetine.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;50</b></td><td headers="hd_h_Atomoxetine.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;397</b></td><td headers="hd_h_Atomoxetine.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Atomoxetine.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Atomoxetine.Comment"><h4>Comment</h4><p>A young girl who had previously taken atomoxetine without difficulty developed an acute, self-limited hepatitis 3 weeks after restarting it. The hepatitis was accompanied by autoantibody formation, but without elevations in globulins or IgG levels. She improved upon stopping atomoxetine and corticosteroids were not used. Drug induced liver injury due to atomoxetine is rare, but several instances of an acute hepatitis-like syndrome arising within 3 to 12 weeks of starting or restarting the medication have been reported in patients without any other obvious reason for acute liver injury. The injury is usually hepatocellular with markedly elevated serum aminotransferase levels (as in this case). Recurrence with reexposure has been reported and should be avoided.</p></div></div></div><div id="Atomoxetine.PRODUCT_INFORMATION"><h2 id="_Atomoxetine_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Atomoxetine.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Atomoxetine &#x02013; Generic, Strattera&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Central Nervous System Stimulants</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Atomoxetine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Atomoxetine.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Atomoxetine_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Atomoxetine.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548671/table/Atomoxetine.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Atomoxetine.T3_lrgtbl__"><table><thead><tr><th id="hd_h_Atomoxetine.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Atomoxetine.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Atomoxetine.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Atomoxetine.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Atomoxetine.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Atomoxetine</td><td headers="hd_h_Atomoxetine.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">83015-26-3</td><td headers="hd_h_Atomoxetine.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C17-H21-N-O</td><td headers="hd_h_Atomoxetine.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548671/bin/Atomoxetine_Structure.jpg" alt="Chemical Structure for Atomoxetine" /></div></td></tr></tbody></table></div></div></div><div id="Atomoxetine.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Atomoxetine_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 27 July 2017</p><p>Abbreviations: ADHD, attention deficit hyperactivity disorder</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Atomoxetine.R1">Zimmerman HJ. Psychotropic and anticonvulsant agents. In, Zimmerman, HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 483-516.<div><i>(Expert review of hepatotoxicity published in 1999; atomoxetine is not mentioned).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R2">Larrey D, Ripault MP. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 443-62.<div><i>(Review of hepatotoxicity of antidepressants; atomoxetine is not discussed).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R3">O'Donnell JM, Shelton RC. Pharmacotherapy of depression and anxiety disorders. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 397-416.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R4">Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 2004; 64: 205-22.  [<a href="/pubmed/14717619" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14717619</span></a>]<div><i>(Review of pharmacology, clinical efficacy and safety of atomoxetine in attention deficit hyperactivity disorder [ADHD]; common side effects are dry mouth, insomnia, nausea, poor appetite, constipation, dizziness, sweating, sexual dysfunction and palpitations; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R5">Drugs for treatment of ADHD. Treat Guidel Med Lett 2006; 4: 77-82.  [<a href="/pubmed/17039210" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17039210</span></a>]<div><i>(Drugs approved for use in ADHDr in the US include atomoxetine, amphetamines and methylphenidate; common side effects of atomoxetine include somnolence, nausea and decreased appetite; &#x0201c;Hepatic toxicity has been reported rarely&#x0201d;).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R6">Lim JR, Faught PR, Chalasani NP, Molleston JP. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr 2006; 148: 831-4.  [<a href="/pubmed/16769398" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16769398</span></a>]<div><i>(Two cases; 12 year old girl developed jaundice 3 weeks after restarting atomoxetine [bilirubin 9.1 mg/dL, ALT 3264 U/L, Alk P 231 U/L, ANA 1:160, IgG 769 mg/dL], resolving in 8 weeks of stopping [Case 1]; 11 year old girl developed fatigue 3 months after starting atomoxetine [bilirubin 0.5 mg/dL, ALT 675 U/L, Alk P 96 U/L, ANA 1:320, IgG 7,390 mg/dL] and biopsy suggesting chronic hepatitis, hepatitis improving within a few weeks of starting prednisone).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R7">Stojanovski SD, Casavant MJ, Mousa HM, Baker P, Nahata MC. Atomoxetine-induced hepatitis in a child. Clin Toxicol (Phila) 2007; 45: 51-5.  [<a href="/pubmed/17357382" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17357382</span></a>]<div><i>(8 year old female developed abdominal pain 1 month after starting atomoxetine [bilirubin 10.8 mg/dL, ALT 5182 U/L, Alk P 528 U/L, ANA negative], resolving within 2 months of stopping; also describes 2 cases reported to FDA: 14 year old boy and 31 year old woman developed symptoms 2.5-3.5 months after starting atomoxetine [bilirubin 1.2 and 16 mg/dL, ALT 31-36 times ULN, Alk P normal], resolving in 2-4 months).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R8">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.  [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, atomoxetine accounted for 3 cases [1%], 2 of which had been previously reported [Lim 2006]).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R9">Bangs ME, Jin L, Zhang S, Desaiah D, Allen AJ, Read HA, Regev A, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008; 31: 345-54.  [<a href="/pubmed/18366245" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18366245</span></a>]<div><i>(Review of hepatic adverse events of atomoxetine; of 7961 patients treated in clinical trials, 41 had hepatobiliary events, but most were mild increases in ALT and none had jaundice with hepatitis; since marketing, there have been 351 spontaneous reports of liver adverse events, but only 3 were considered probable, one of which had a positive rechallenge).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R10">Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009; 11: 203-26.  [<a href="/pubmed/19445548" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19445548</span></a>]<div><i>(Review of mechanism of action, pharmacology, clinical efficacy and safety of atomoxetine as treatment of ADHD in children; common side effects are headache, abdominal pain, decreased appetite, nausea, somnolence, fatigue, irritability and dizziness; mild elevations in ALT or AST occur in 0.5% of subjects, and the sponsor has received reports of 351 hepatic adverse events from an estimated 4.3 million recipients [&#x0003c;0.01%]).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R11">Johnson M, Cederlund M, R&#x000e5;stam M, Areskoug B, Gillberg C. Open-label trial of atomoxetine hydrochloride in adults with ADHD. J Atten Disord 2010; 13: 539-45.  [<a href="/pubmed/19458384" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19458384</span></a>]<div><i>(Open label trial of atomoxetine in 20 adults with ADHD; one patient discontinued drug because of raised liver enzymes; no details given).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R12">Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, Sturkenboom MC. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. Br J Clin Pharmacol 2010; 70: 721-8.  [<a href="/pmc/articles/PMC2997312/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2997312</span></a>] [<a href="/pubmed/21039766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21039766</span></a>]<div><i>(World wide pharmacovigilance database contained 9036 hepatic adverse drug reactions in children, 2 agents used for ADHD were among the top 41 causes; methylphenidate [11th, 96 cases] and atomoxetine [14th, 64 cases]).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R13">Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010; 105: 2396-404.  [<a href="/pubmed/20648003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20648003</span></a>]<div><i>(Among 313 cases of drug induced liver injury seen between 1997 and 2008 at a large hospital in Bangalore, India, one case was attributed to atomoxetine).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R14">Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.  [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i> (Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, including one attributed to cocaine and one to ecstasy but none to atomoxetine).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R15">Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N: Drug-induced Liver Injury Network. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr 2011; 53: 182-9.  [<a href="/pmc/articles/PMC3634369/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3634369</span></a>] [<a href="/pubmed/21788760" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21788760</span></a>]<div><i>(Among 30 children with suspected drug induced liver injury, 3 were attributed to atomoxetine and one to methylphenidate).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R16">Erdogan A, Ozcay F, Piskin E, Karaman MG, Bilezikci B, Calik M, Tekin I, et al. Idiosyncratic liver failure probably associated with atomoxetine: a case report. J Child Adolesc Pscyhopharmacol 2011; 21: 295-7.  [<a href="/pubmed/21663435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21663435</span></a>]<div><i>(10 year old boy developed fatigue 2 days and jaundice 5 days after starting atomoxetine [bilirubin 5.2 rising to 23.0 mg/dL, ALT 942 to 2832 U/L, Alk P 400 U/L, INR 4.1], with progressive liver failure, encephalopathy and emergency living donor liver transplantation).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R17">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, Presentation and Outcomes in Patients with Drug-Induced Liver Injury in the General Population of Iceland. Gastroenterology 2013; 144: 1419-25.  [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were attributed to atomoxetine).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R18">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. Ann Hepatol 2014; 13: 231-9.  [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, none were attributed to atomoxetine).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R19">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-1352.e7. <em>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 4 [0.5%] were attributed to atomoxetine)</em> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>.</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R20">Cortese S, Panei P, Arcieri R, Germinario EA, Capuano A, Margari L, Chiarotti F, et al. Safety of methylphenidate and atomoxetine in children with attention-deficit/ hyperactivity disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs 2015; 29: 865-77.  [<a href="/pubmed/26293742" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26293742</span></a>]<div><i>(The Italian ADHD Registry of children treated with methylphenidate [n=1350] and atomoxetine [n=753] included adverse events reports in 27% of cases and serious events in 4%, more frequently with atomoxetine among which were 3 cases of hyperbilirubinemia which were considered possibly life-threatening).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R21">Camporeale A, Porsdal V, De Bruyckere K, Tanaka Y, Upadhyaya H, Deix C, Deberdt W. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials. J Psychopharmacol 2015; 29: 3-14.  [<a href="/pubmed/25424623" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25424623</span></a>]<div><i> (Among 4829 patients enrolled in 15 placebo controlled trials of atomoxetine in adults with ADHD, rates of serious adverse events were similar in the two groups and there were no differences in changes in ALT or in numbers of liver-related serious adverse events).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R22">Drugs for ADHD. Med Lett Drugs Ther 2015; 57 (1464): 37-40.  [<a href="/pubmed/25758544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25758544</span></a>]<div><i>(Concise review of the mechanism of action, clinical efficacy, safety and costs of drugs approved for use in ADHD, including atomoxetine and methylphenidate; no mention of ALT elevations or hepatotoxicity of either drug).</i></div></div></li><li><div class="bk_ref" id="Atomoxetine.R23">Tumuluru RV, Corbett-Dick P, Aman MG, Smith T, Arnold LE, Pan X, Buchan-Page KA, et al. Adverse events of atomoxetine in a double-blind placebo-controlled study in children with autism. J Child Adolesc Psychopharmacol 2017 May 16. [Epub ahead of print]  [<a href="/pmc/articles/PMC5651962/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5651962</span></a>] [<a href="/pubmed/28509573" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28509573</span></a>]<div><i>(Among 128 children with ADHD treated with atomoxetine alone or with parent training or with placebo and parent training, adverse events linked to atomoxetine included decrease in appetite and fatigue, and "no significant difference of changes in laboratory tests was noted" between the groups).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548671</span><span class="label">PMID: <a href="/pubmed/31643982" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643982</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Atezolizumab/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Atorvastatin/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548671&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548671/?report=reader">PubReader</a></li><li><a href="/books/NBK548671/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548671" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548671" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Atomoxetine. [Updated 2017 Jul 27].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548671/pdf/Bookshelf_NBK548671.pdf">PDF version of this page</a> (112K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=atomoxetine+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Atomoxetine: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=atomoxetine" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Atomoxetine: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4863674" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4863674" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/19445548" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.</a><span class="source">[Paediatr Drugs. 2009]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Garnock-Jones KP, Keating GM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Paediatr Drugs. 2009; 11(3):203-26. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/21864451" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder.</a><span class="source">[Cardiol Young. 2012]</span><div class="brieflinkpop offscreen_noflow">Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sert A, Gokcen C, Aypar E, Odabas D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cardiol Young. 2012 Apr; 22(2):158-61. Epub 2011 Aug 25.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27290715" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.</a><span class="source">[CNS Drugs. 2016]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Reed VA, Buitelaar JK, Anand E, Day KA, Treuer T, Upadhyaya HP, Coghill DR, Kryzhanovskaya LA, Savill NC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">CNS Drugs. 2016 Jul; 30(7):603-28. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29608930" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Atomoxetine, a selective norepinephrine reuptake inhibitor, improves short-term histological outcomes after hypoxic-ischemic brain injury in the neonatal male rat.</a><span class="source">[Int J Dev Neurosci. 2018]</span><div class="brieflinkpop offscreen_noflow">Atomoxetine, a selective norepinephrine reuptake inhibitor, improves short-term histological outcomes after hypoxic-ischemic brain injury in the neonatal male rat.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Toshimitsu M, Kamei Y, Ichinose M, Seyama T, Imada S, Iriyama T, Fujii T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Int J Dev Neurosci. 2018 Nov; 70:34-45. Epub 2018 Mar 30.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14717619" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.</a><span class="source">[Drugs. 2004]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Simpson D, Plosker GL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs. 2004; 64(2):205-22. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643982" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643982" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60467833ddcb804c59b3dcd9">Atomoxetine - LiverTox</a><div class="ralinkpop offscreen_noflow">Atomoxetine - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:17:07-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal101&amp;ncbi_phid=CE8810BD0466D11100000000029E00B5&amp;ncbi_session=CE8810BD04678321_0670SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548671%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548671&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548671/&amp;ncbi_pagename=Atomoxetine - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8810BD04678321_0670SID /projects/books/PBooks@9.2 portal101 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>